ERBB2 and breast carcinoma: Identification of MZF1 as an oncogenic target of PAK4, whose activity is important for invasiveness of ErbB2 positive breast cancer cells, suggests that PAK4 inhibitors might be useful for the treatment of cancers whose aggressiveness depends on MZF1.